Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer

References

• Siegel, R, Naishadham, D, Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
   PubMed Web of Science ®Google Scholar
• Ferlay, J, Steliarova-Foucher, E, Lortet-Tieulent, J, Rosso, S, Coebergh, JW, Comber, H, Forman, D, Bray, F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-1403; PMID:23485231; http://dx.doi.org/10.1016/j.ejca.2012.12.027
   PubMed Web of Science ®Google Scholar
• Babjuk, M, Burger, M, Zigeuner, R, Shariat, SF, van Rhijn, BW, Comperat, E., Sylvester, RJ, Kaasinen, E, Bohle, A, Palou Redorta, J et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64:639-653; PMID:23827737; http://dx.doi.org/10.1016/j.eururo.2013.06.003
   PubMed Web of Science ®Google Scholar
• Gontero, P, Bohle, A, Malmstrom, PU, O'Donnell, MA, Oderda, M, Sylvester, R, Witjes, F. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57:410-429; PMID:19969411; http://dx.doi.org/10.1016/j.eururo.2009.11.023
   PubMed Web of Science ®Google Scholar
• Kamat, AM, Sylvester, RJ, Bohle, A, Palou, J, Lamm, DL, Brausi, M, Soloway, M, Persad, R, Buckley, R, Colombel, M et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 2016; 34:1935-44; PMID:26811532; http://dx.doi.org/10.1200/JCO.2015.64.4070
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi, G, Glickman, MS, Bochner, BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 2014; 11:153-162; PMID:24492433; http://dx.doi.org/10.1038/nrurol.2014.15
   PubMed Web of Science ®Google Scholar
• Guzman, CA, Borsutzky, S, Griot-Wenk, M, Metcalfe, IC, Pearman, J, Collioud, A, Favre, D, Dietrich, G. Vaccines against typhoid fever. Vaccine 2006; 24:3804-11; PMID:16278037; http://dx.doi.org/10.1016/j.vaccine.2005.07.111
   PubMed Web of Science ®Google Scholar
• Summerhayes, IC, Franks, LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 1979; 62:1017-23; PMID:107359
   PubMedGoogle Scholar
• Günther, JH, Jurczok, A, Wulf, T, Brandau, S, Deinert, I, Jocham, D, Böhle, A. Optimizing syngeneic otrhotopic murine bladder cancer (MB49). Cancer Res 1999; 59:2834-37; PMID:10383142
   PubMed Web of Science ®Google Scholar
• Suttmann, H, Riemensberger, J, Bentien, G, Schmaltz, D, Stöckle, M, Jocham, D, Böhle, A, Brandau, S. Neutrophil granulocytesare required for effective Bacilus Calmette-Guérin Imunotherapy of bladder cancer and orchestrate local immune reponses. Cancer Res 2006; 16:8250-57; PMID:16912205; http://dx.doi.org/10.1158/0008-5472.CAN-06-1416
   PubMed Web of Science ®Google Scholar
• Loskog, A, Fransson, ME, Totterman, TH. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orhotopic bladder cancer model. Clin. Cancer Res 2005; 24:8816-21; PMID:16361570; http://dx.doi.org/10.1158/1078-0432.CCR-05-1817
   PubMed Web of Science ®Google Scholar
• Mangsbo, SM, Nanalga, C, Essand, M, Loskog, A, Totterman, TH. CpG therapy is superior to BCG in an otrhotopic bladder cancer model and generates CD4+ T -cell immunity. J. Immunother 2008; 31:34-42; PMID:18157010; http://dx.doi.org/10.1097/CJI.0b013e3181587d29
   PubMed Web of Science ®Google Scholar
• Jurczok, A, Fornara, P, Soling, A. Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. BJU Int 2008; 101:120-4; PMID:17888045; http://dx.doi.org/10.1111/j.1464-410X.2007.07193.x
   PubMed Web of Science ®Google Scholar
• Galen, JE, Gomezduarte, OG, Losonsky, GA, Halpern, JL, Lauderbaugh, CS, Kaintuck, S, Reymann, MK, Levine, MM. A murine model of intranasal immunization to assess the immunogenicity of attenuated salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 1997; 15:700-8; PMID:9178472; http://dx.doi.org/10.1016/S0264-410X(96)00227-7
   PubMed Web of Science ®Google Scholar
• Fraillery, D, Baud, D, Pang, SY, Schiller, J, Bobst, M, Zosso, N, Ponci, F, Nardelli-Haefliger, D. Ty21a expressing Human papillomavirus type 16 L1 as a potential live Salmonella vaccine against cervical cancer and typhoid fever. Clin. Vaccine Immunol 2007; 14:1285-95; PMID:17687110; http://dx.doi.org/10.1128/CVI.00164-07
   PubMed Web of Science ®Google Scholar
• Bisiaux, A, Thiounn, N, Timsit, MO, Eladaoui, A, Chang, HH, Mapes, J, Mogenet, A, Bresson, JL, Prie, D, Bechet, S. et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol 2009; 181:1571-80; PMID:19230924; http://dx.doi.org/10.1016/j.juro.2008.11.124
   PubMed Web of Science ®Google Scholar
• Askeland, EJ, Newton, MR, O'Donnell, MA, Luo, Y. Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol 2012; 2012:181987; PMID:22778725; http://dx.doi.org/10.1155/2012/181987
   PubMedGoogle Scholar
• Fiorentino, M, Lammers, KM, Levine, MM, Sztein, MB, Fasano, A. In vitro intestinal mucosal epithelial responses to wild-type salmonella typhi and attenuated typhoid vaccines. Front Immunol 2013; 4:17; PMID:23408152; http://dx.doi.org/10.3389/fimmu.2013.00017
   PubMed Web of Science ®Google Scholar
• Broz, P, Ohlson, MB, Monack, DM. Innate immune response to Salmonella typhimurium, a model enteric pathogen. Gut Microbes 2012; 3:62-70; PMID:22198618; http://dx.doi.org/10.4161/gmic.19141
   PubMedGoogle Scholar
• Raymond, B, Young, JC, Pallett, M, Endres, RG, Clements, A, Frankel, G. Subversion of trafficking, apoptosis, and innate immunity by type III secretion system effectors. Trends Microbiol 2013; 21:430-441; PMID:23870533; http://dx.doi.org/10.1016/j.tim.2013.06.008
   PubMed Web of Science ®Google Scholar
• Thalmann, GN, Sermier, A, Rentsch, C, Mohrle, K, Cecchini, MG, Studer, UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000; 164:2129-33; PMID:11061941; http://dx.doi.org/10.1016/S0022-5347(05)66983-2
   PubMed Web of Science ®Google Scholar
• Zuiverloon, TC, Nieuweboer, AJ, Vekony, H, Kirkels, WJ, Bangma, CH, Zwarthoff, EC. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012; 61:128-145; PMID:22000498; http://dx.doi.org/10.1016/j.eururo.2011.09.026
   PubMed Web of Science ®Google Scholar
• Luo, Y, Henning, J, O'Donnell, MA. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol 2011; 2011:728930; PMID:21941579; http://dx.doi.org/10.1155/2011/728930
   PubMedGoogle Scholar
• Kucerova, P, Cervinkova, M. Spontaneous regression of tumour and the role of microbial infection–possibilities for cancer treatment. Anticancer Drugs 2016; 27:269-277; PMID:26813865; http://dx.doi.org/10.1097/CAD.0000000000000337
   PubMed Web of Science ®Google Scholar
• Shi, H, Santander, J, Brenneman, KE, Wanda, SY, Wang, S, Senechal, P, Sun, W, Roland, KL, Curtiss, R. Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS One 2010; 5:e11142; PMID:20585446; http://dx.doi.org/10.1371/journal.pone.0011142
   PubMed Web of Science ®Google Scholar
• Babjuk, M, Bohle, A, Burger, M, Capoun, O, Cohen, D, Comperat, EM, Hernandez, V, Kaasinen, E, Palou, J, Roupret, M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 2016; 30249-4; PMID:27324428; http://dx.doi.org/10.1016/j.eururo.2016.05.041
   PubMedGoogle Scholar
• Nardelli-Haefliger, D, Roden, R, Benyacoub, J, Sahli, R, Kraehenbuhl, JP, Schiller, JT, Lachat, P, Potts, A, Degrandi, P. Human papillomavirus type 16 virus-like particles expressed in attenuated salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infection & Immunity 1997; 65:3328-3336; PMID:9234794
   PubMed Web of Science ®Google Scholar